News
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
-
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company's proprietary ai²™ division. Dr. Kramer brings more than 30 year.07/15/2025
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
-
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol “APUS.”05/12/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions
Is Apimeds Pharmaceuticals US, Inc (APUS) a buy, sell, or hold?
Apimeds Pharmaceuticals US, Inc (APUS) can sell. Click on Rating Page for detail.
What is Apimeds Pharmaceuticals US, Inc's stock price?
The price of Apimeds Pharmaceuticals US, Inc (APUS) is 1.61 and it was updated on 2025-08-13 02:51:49.
Is Apimeds Pharmaceuticals US, Inc (APUS) overvalued or undervalued?
Currently Apimeds Pharmaceuticals US, Inc (APUS) is in overvalued.
News
| News |
|---|
 U.S. IPO Weekly Recap: Sizable Insurance IPOs Deliver Solid Trading
|
SEC Filings
Press Releases
| StockPrice Release |
|---|
APUS Ratings Summary
APUS Quant Ranking
